Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRDL
stocks logo

CRDL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.100
+11.11%
--
--
-0.105
+5%
--
--
-0.105
+5%
Estimates Revision
The market is revising No Change the revenue expectations for Cardiol Therapeutics Inc. (CRDL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -11.80%.
EPS Estimates for FY2025
Revise Upward
up Image
+3.17%
In Past 3 Month
Stock Price
Go Down
down Image
-11.80%
In Past 3 Month
Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.25 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.25 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.961
sliders
Low
6.00
Averages
8.25
High
10.00
Current: 0.961
sliders
Low
6.00
Averages
8.25
High
10.00
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$9
2025-06-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-06-02
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-04-16
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2025-04-16
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-04-07
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2025-04-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2025-02-24
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2025-02-24
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$9
2024-12-18
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$9
2024-12-18
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cardiol Therapeutics Inc (CRDL.O) is -3.23, compared to its 5-year average forward P/E of -4.11. For a more detailed relative valuation and DCF analysis to assess Cardiol Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.11
Current PE
-3.23
Overvalued PE
-2.22
Undervalued PE
-5.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.69
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.84
Undervalued EV/EBITDA
-6.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
24.33
Current PS
0.00
Overvalued PS
92.99
Undervalued PS
-44.34
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CRDL News & Events

Events Timeline

(ET)
2025-08-06
11:45:52
Roth bullish on Cardiol, says trial results enough to attract larger partner
select
2025-08-06
10:08:13
Cardiol ARCHER study not statistically significant, says Canaccord
select
2025-08-06
09:12:05
Cardiol data readout positive and not priced in, says H.C. Wainwright
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-02Benzinga
MongoDB Shares Surge Over 22%; Check Out 20 Stocks Making Moves in Premarket Trading

  • MongoDB's Strong Performance: MongoDB Inc. shares surged 22.8% in pre-market trading after reporting third-quarter revenue of $628.31 million, exceeding analyst expectations, and raising its FY26 guidance.

  • Other Notable Gainers: Taoping Inc. saw a 64.5% increase after announcing an acquisition, while Fitell Corp. rose 37.6% following a repurchase program announcement.

  • Significant Losers: Janux Therapeutics Inc. experienced a 39.3% drop in pre-market trading after releasing updated interim data, while American Bitcoin Corp. fell 17% after a previous decline.

  • Market Overview: The article highlights various stocks moving in pre-market trading, showcasing both significant gainers and losers, reflecting market volatility.

[object Object]
Preview
4.0
12-02Benzinga
HC Wainwright & Co. Affirms Buy Rating for Cardiol Therapeutics, Keeps $9 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders succeed in the markets.

  • Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from timely alerts and insights.

  • Trade Alerts: Users can receive the fastest news alerts to ensure they never miss a trading opportunity.

[object Object]
Preview
9.0
07-22NASDAQ.COM
Cardiol To Report ARCHER Study Data Within The Next Two Weeks

  • Clinical Milestone for Cardiol Therapeutics: Cardiol Therapeutics Inc. is nearing a significant milestone with its lead asset, CardiolRx, an oral solution in clinical development for heart disease, specifically in a phase II study for acute myocarditis called ARCHER, which has enrolled over 100 patients across multiple countries.

  • Database Lock and Upcoming Results: The company has completed the database lock for the ARCHER study, a crucial step before statistical analysis, with topline results expected within two weeks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cardiol Therapeutics Inc (CRDL) stock price today?

The current price of CRDL is 0.9614 USD — it has increased 1.8 % in the last trading day.

arrow icon

What is Cardiol Therapeutics Inc (CRDL)'s business?

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

arrow icon

What is the price predicton of CRDL Stock?

Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.25 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cardiol Therapeutics Inc (CRDL)'s revenue for the last quarter?

Cardiol Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Cardiol Therapeutics Inc (CRDL)'s earnings per share (EPS) for the last quarter?

Cardiol Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, decreased -33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cardiol Therapeutics Inc (CRDL)'s fundamentals?

The market is revising No Change the revenue expectations for Cardiol Therapeutics Inc. (CRDL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -11.80%.
arrow icon

How many employees does Cardiol Therapeutics Inc (CRDL). have?

Cardiol Therapeutics Inc (CRDL) has 18 emplpoyees as of December 05 2025.

arrow icon

What is Cardiol Therapeutics Inc (CRDL) market cap?

Today CRDL has the market capitalization of 96.50M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free